MORGAN STANLEY INCREASES TARGET PRICE FOR UNITEDHEALTH GROUP INC TO $395.00, UP FROM $375.00
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy UNH?
Source: moomoo
Price Increase Announcement: United Health Group has raised the target price for Morgan Stanley from $375.00 to $395.00.
Market Implications: This adjustment reflects a positive outlook on Morgan Stanley's performance and potential growth in the financial sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UNH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UNH
Wall Street analysts forecast UNH stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 354.560
Low
330.00
Averages
397.82
High
444.00
Current: 354.560
Low
330.00
Averages
397.82
High
444.00
About UNH
UnitedHealth Group Incorporated is a healthcare and well-being company. Its segments include Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State. Optum Health provides comprehensive and patient-centered care, addressing the physical, mental, and social well-being. Optum Health delivers primary, specialty and surgical care and helps patients and providers navigate and address complex, chronic and behavioral health needs. Optum Insight connects the healthcare system with services, analytics and platforms that make clinical, administrative and financial processes simpler and more efficient for all participants in the healthcare system. Optum Rx offers a range of pharmacy care services through retail pharmacies, through home delivery, specialty and community health pharmacies and the provision of in-home and community-based infusion services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UNITEDHEALTH: BOFA GLOBAL RESEARCH INCREASES PRICE TARGET TO $380 FROM $371
Global Health Research Funding Increase: The United Health organization has raised its funding objective for global health research from $371 million to $380 million.
Focus on Health Initiatives: This increase in funding aims to support various health initiatives and research projects worldwide, addressing critical health challenges.
See More
UnitedHealthcare Advances Standardization of Prior Authorization Process
- Accelerated Standardization: UnitedHealthcare announced that over 70% of its prior authorization volume will be included in a standardized submission process by the end of 2026, aiming to simplify administrative requirements for healthcare services, thereby enhancing accessibility and efficiency.
- Strengthened Industry Collaboration: This initiative reflects UnitedHealthcare's collaboration with other health plans to promote standardization in electronic prior authorization submissions, which is expected to improve experiences for healthcare providers and patients, saving time and costs.
- Technology Tool Upgrades: The company plans to leverage digital tools for electronic submissions, real-time status tracking, and faster decision-making, further reducing the need and volume of prior authorizations while ensuring the safety and clinical basis of healthcare services.
- Commitment to Continuous Improvement: UnitedHealthcare is dedicated to enhancing predictability in prior authorizations and reducing requests for additional information, ensuring that these changes do not impact clinical policies or coverage determinations, thereby reinforcing its leadership in modernizing healthcare administration.
See More
Analyst Blog Stock Recommendations
- UnitedHealth Performance: UnitedHealth Group (UNH) has seen a 0.6% decline in stock price over the past six months, compared to a 3.4% drop in the HMO industry, indicating rising medical cost pressures, although Q1 earnings exceeded estimates with total revenue expected to surpass $439 billion in 2026.
- Morgan Stanley Growth: Morgan Stanley (MS) shares have risen 17.4% over the past six months, outperforming the investment banking industry’s 6.2%, with Q1 results showcasing strength in capital markets and the acquisition of EquityZen expected to enhance client relationships and drive revenue growth.
- RTX Strong Orders: RTX Corporation (RTX) has outperformed with a 2.1% stock price increase over the past six months, with Q1 earnings beating expectations and a robust order backlog of $271 billion supporting future growth, despite uncertainties from U.S. government import tariffs.
- Microcap Underperformance: United Homes Group (UHG) has underperformed with a 32.4% stock price decline over the past six months, reflecting weak demand and declining orders, although product repositioning and cost reengineering are supporting structural margin resilience.
See More
Investors Should Focus on Undervalued Healthcare Stocks
- Market Opportunity Identification: CNBC's Jim Cramer urged investors to look at undervalued sectors, particularly healthcare stocks, which appear more attractive amidst the tech surge, providing diversification for portfolios.
- CVS Health's Market Advantage: Cramer highlighted CVS Health's benefits from a changing competitive landscape, as rivals like Rite Aid disappear and Walgreens scales back, allowing CVS to effectively increase market share through its insurance arm Aetna and numerous retail locations.
- Cardinal Health's Transformation: Cramer noted that Cardinal Health has been unfairly punished without clear reason, yet the company is transitioning from a traditional drug distributor to higher-growth services, particularly in supporting specialty medical practices, showcasing future growth potential.
- Johnson & Johnson's Strong Foundation: Cramer emphasized Johnson & Johnson's robust balance sheet and pipeline of potential blockbuster drugs, coupled with CEO Stephen Hemsley's return, which has bolstered market confidence in its ability to sustain growth.
See More
Investors Should Focus on Undervalued Healthcare Stocks
- Market Opportunity: Jim Cramer highlighted that despite the S&P 500 and Nasdaq hitting new highs, healthcare stocks are undervalued due to solid fundamentals, suggesting investors focus on these overlooked areas for portfolio diversification.
- CVS Health's Competitive Edge: Cramer emphasized that CVS Health is benefiting from a changing competitive landscape, as rivals like Rite Aid disappear and Walgreens scales back, positioning CVS to capture market share with its insurance arm Aetna and extensive retail locations.
- Cardinal Health's Transformation: Cramer noted that Cardinal Health has been unfairly punished without clear reasons, but the company is shifting from its traditional drug distribution role to higher-growth services, particularly in supporting specialty medical practices.
- Johnson & Johnson's Strong Outlook: Cramer pointed out Johnson & Johnson's robust balance sheet and potential blockbuster pipeline, while the return of CEO Stephen Hemsley has stabilized UnitedHealth Group and restored confidence in its growth trajectory.
See More
UnitedHealth Group's Stock Experiences Wild Fluctuations
- Significant Price Drop: UnitedHealth Group's stock has plummeted over 60% since November 2024, primarily due to surging medical cost inflation and uncertainty from Washington, which has pressured margins and forced the company to lower its guidance.
- Executive Turmoil Impact: The killing of CEO Brian Thompson in New York has added another layer of uncertainty during an already fragile period for the company, negatively affecting investor confidence.
- Institutional Buying: Despite the challenges, large investment firms like Berkshire Hathaway have begun to build positions in the stock, signaling confidence in a potential turnaround and possibly providing price support.
- Positive Technical Signals: The stock has broken a two-year downtrend and is currently above key moving averages; while slightly overbought in the short term, market sentiment is improving, with expectations of a continued rise towards a target price of $375.
See More
UNITEDHEALTH: BOFA GLOBAL RESEARCH INCREASES PRICE TARGET TO $380 FROM $371
Global Health Research Funding Increase: The United Health organization has raised its funding objective for global health research from $371 million to $380 million.
Focus on Health Initiatives: This increase in funding aims to support various health initiatives and research projects worldwide, addressing critical health challenges.
See More
UnitedHealthcare Advances Standardization of Prior Authorization Process
- Accelerated Standardization: UnitedHealthcare announced that over 70% of its prior authorization volume will be included in a standardized submission process by the end of 2026, aiming to simplify administrative requirements for healthcare services, thereby enhancing accessibility and efficiency.
- Strengthened Industry Collaboration: This initiative reflects UnitedHealthcare's collaboration with other health plans to promote standardization in electronic prior authorization submissions, which is expected to improve experiences for healthcare providers and patients, saving time and costs.
- Technology Tool Upgrades: The company plans to leverage digital tools for electronic submissions, real-time status tracking, and faster decision-making, further reducing the need and volume of prior authorizations while ensuring the safety and clinical basis of healthcare services.
- Commitment to Continuous Improvement: UnitedHealthcare is dedicated to enhancing predictability in prior authorizations and reducing requests for additional information, ensuring that these changes do not impact clinical policies or coverage determinations, thereby reinforcing its leadership in modernizing healthcare administration.
See More
Analyst Blog Stock Recommendations
- UnitedHealth Performance: UnitedHealth Group (UNH) has seen a 0.6% decline in stock price over the past six months, compared to a 3.4% drop in the HMO industry, indicating rising medical cost pressures, although Q1 earnings exceeded estimates with total revenue expected to surpass $439 billion in 2026.
- Morgan Stanley Growth: Morgan Stanley (MS) shares have risen 17.4% over the past six months, outperforming the investment banking industry’s 6.2%, with Q1 results showcasing strength in capital markets and the acquisition of EquityZen expected to enhance client relationships and drive revenue growth.
- RTX Strong Orders: RTX Corporation (RTX) has outperformed with a 2.1% stock price increase over the past six months, with Q1 earnings beating expectations and a robust order backlog of $271 billion supporting future growth, despite uncertainties from U.S. government import tariffs.
- Microcap Underperformance: United Homes Group (UHG) has underperformed with a 32.4% stock price decline over the past six months, reflecting weak demand and declining orders, although product repositioning and cost reengineering are supporting structural margin resilience.
See More
Investors Should Focus on Undervalued Healthcare Stocks
- Market Opportunity Identification: CNBC's Jim Cramer urged investors to look at undervalued sectors, particularly healthcare stocks, which appear more attractive amidst the tech surge, providing diversification for portfolios.
- CVS Health's Market Advantage: Cramer highlighted CVS Health's benefits from a changing competitive landscape, as rivals like Rite Aid disappear and Walgreens scales back, allowing CVS to effectively increase market share through its insurance arm Aetna and numerous retail locations.
- Cardinal Health's Transformation: Cramer noted that Cardinal Health has been unfairly punished without clear reason, yet the company is transitioning from a traditional drug distributor to higher-growth services, particularly in supporting specialty medical practices, showcasing future growth potential.
- Johnson & Johnson's Strong Foundation: Cramer emphasized Johnson & Johnson's robust balance sheet and pipeline of potential blockbuster drugs, coupled with CEO Stephen Hemsley's return, which has bolstered market confidence in its ability to sustain growth.
See More
Investors Should Focus on Undervalued Healthcare Stocks
- Market Opportunity: Jim Cramer highlighted that despite the S&P 500 and Nasdaq hitting new highs, healthcare stocks are undervalued due to solid fundamentals, suggesting investors focus on these overlooked areas for portfolio diversification.
- CVS Health's Competitive Edge: Cramer emphasized that CVS Health is benefiting from a changing competitive landscape, as rivals like Rite Aid disappear and Walgreens scales back, positioning CVS to capture market share with its insurance arm Aetna and extensive retail locations.
- Cardinal Health's Transformation: Cramer noted that Cardinal Health has been unfairly punished without clear reasons, but the company is shifting from its traditional drug distribution role to higher-growth services, particularly in supporting specialty medical practices.
- Johnson & Johnson's Strong Outlook: Cramer pointed out Johnson & Johnson's robust balance sheet and potential blockbuster pipeline, while the return of CEO Stephen Hemsley has stabilized UnitedHealth Group and restored confidence in its growth trajectory.
See More
UnitedHealth Group's Stock Experiences Wild Fluctuations
- Significant Price Drop: UnitedHealth Group's stock has plummeted over 60% since November 2024, primarily due to surging medical cost inflation and uncertainty from Washington, which has pressured margins and forced the company to lower its guidance.
- Executive Turmoil Impact: The killing of CEO Brian Thompson in New York has added another layer of uncertainty during an already fragile period for the company, negatively affecting investor confidence.
- Institutional Buying: Despite the challenges, large investment firms like Berkshire Hathaway have begun to build positions in the stock, signaling confidence in a potential turnaround and possibly providing price support.
- Positive Technical Signals: The stock has broken a two-year downtrend and is currently above key moving averages; while slightly overbought in the short term, market sentiment is improving, with expectations of a continued rise towards a target price of $375.
See More
